New hope for Tough-to-Treat lymphoma: drug combo trial launches
NCT ID NCT07159906
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times
Summary
This study tests a new combination of drugs for adults with diffuse large B-cell lymphoma that has come back or not responded to standard treatments. The goal is to see if adding homoharringtonine and a BCL-2 inhibitor to rituximab and prednisone can safely shrink tumors. About 62 participants will take part across two phases to find the best dose and measure response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.